Today's Must Read
Strong GPU Adoption in Gaming, Datacenter Aids NVIDIA (NVDA)
Business Restructuring Aids HSBC (HSBC), Weak Revenues a Woe
Wednesday, June 23, 2021
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), NVIDIA (NVDA), and HSBC Holdings (HSBC). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Facebook have outperformed the S&P 500 in the year-to-date period (+24.4% vs. +14.7%). The Zacks analyst believes that Facebook has been benefiting from steady user growth across all regions, particularly Asia Pacific. Increased engagement for its products like Instagram, WhatsApp and Messenger is another growth driver.
For second quarter of 2021, it expects year-over-year revenue growth to remain stable compared with the first quarter of 2021. However, Facebook expects changes made by Apple in its iOS 14 platform to limit the latter’s ability to track user-activity trend. The company also believes that Apple has become its biggest competitor.
NVIDIA shares have gained +46.3% over the last six months against the Zacks General Semiconductor industry’s gain of +31.3%. The Zacks analyst believes that NVIDIA has been gaining from the pandemic-induced work-from-home and learn-at-home trend. It is also benefiting from strong growth in GeForce desktop and notebook GPUs, which is boosting gaming revenues.
Moreover, a surge in Hyperscale demand remains a tailwind for the company’s Data Center business. Also, expansion of NVIDIA GeForce NOW is expected to drive its user base. However, management expects COVID-19 pandemic to negatively impact near-term revenues. Moreover, the U.S.-China trade war remains a key concern.
Shares of HSBC have gained +2.1% in the past three months against the Zacks Foreign Banks industry’s gain of +8.1%. The Zacks analyst believes that initiatives to improve market share in the U.K. and China are likely to support the company’s financials.
Also, the company’s strong capital position and its efforts to improve operating efficiency through business restructuring are expected to support profitability. However, these efforts might lead to a continued rise in expenses, which will likely hurt the bottom-line growth. Moreover, the persistent low interest rate environment and weak loan demand are expected to continue weighing on revenue growth in the near term.
Other noteworthy reports we are featuring today include S&P Global (SPGI), Ford Motor (F) and Pioneer Natural Resources (PXD).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>